The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies is also promising, which could become a new therapeutic tool in blocking tumor immune escape in NSCLC [111]. The gene discussed is KIR3DL1; the disease is non-small cell lung carcinoma.